MRSA Drugs Market To Reflect Impressive Growth Rate During 2025

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that causes infections in different body parts. The symptoms are varied and depend on the infected area. It causes minor skin infections on the body, but also causes serious ailments by infecting blood-vessel, urinary tract, abscesses, breast, bone, mucosal surfaces, or even implanted devices. Large number of people carry MRSA without being infected; however, MRSA causes problems when it enters the body through a cut. People with low immunity are mostly infected with MRSA. Additionally, people working in hospitals, clinics, and other health care organizations are prone to MRSA infections. Even people who live in closed communities such as prisons, sports camps, or asylums have high chance of being infected with MRSA.

The global prevalence of MRSA varies among several countries. The infection rate is as low as 5% in Iceland and as high as 70% in Romania. Several clinical studies have found that MRSA is mostly treated with common antibacterial drugs. However, some stains of MRSA are resistant to these drugs. The Global MRSA Drugs Market is driven by several factors such as higher population, sense of hygiene, public awareness about MRSA, diagnosis rate, treatment rate, and government initiatives to highlight the seriousness of MRSA infections. However, the market is likely to face several challenges such as different drug regulatory scenarios, risk of drug counterfeiting, expensive drug pricing strategies, and lack of contribution from distribution channels.

Vancomycin is preferred for MRSA treatment; however, patients who have been using the drug for longer period could develop resistance to Vancomycin for MRSA treatment. Several clinical studies have proved that Vancomycin-resistant MRSA cases can be treated with Daptomycin, Linezolid, Quinupristine/Dalfopristin, Ceftaroline, or combination of Trimethoprim and Sulfamethoxazole. Based on class of antibiotic, the global MRSA drugs market can be classified into glycopeptide, lipopeptide, oxazolidinones, streptogramins, cephalosporins, and others. Most of these are administered to patients orally, some are injected parenterally, and rarely administered topically. Based on route of administration, the MRSA drugs market can be classified into enteral, parenteral, and others.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1315

The Centers for Disease Control and Prevention has classified MRSA infected patients into hospital acquired MRSA (HA-MRSA) and community associated MRSA (CA-MRSA). HA-MRSA patients are those who work in health care organizations and have been infected from associated areas. CA-MRSA patients contract the infection from closed community activities. In terms of end-user, the MRSA drugs market can be categorized into HA-MRSA and CA-MRSA.

MRSA drugs can be dispensed through hospital pharmacies and drug stores/retail pharmacies. Additionally, e-pharmacies fulfill the orders of MRSA drugs over the Internet. However, the participation of shipping companies in e-pharmacy is crucial and multiple drug regulatory authorities are against of online sales of MRSA drugs. Based on distribution channel, the global MRSA drug market can be divided into hospital pharmacies, retail pharmacies, and online sales.

The global MRSA drugs market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a major market for MRSA drugs due to high MRSA infection rate, public awareness, high diagnosis and treatment rates, and availability and affordability of drugs. Europe held the second largest market share owing to high prevalence of MRSA infection and high treatment rate. The MRSA infection rate is also high in the eastern part of Asia Pacific, but is not higher than the infection rate of MRSA in the U.S. Brazil, Columbia, and Argentina exhibit higher prevalence of MRSA as compared to the U.S. The MRSA infection rate in the Middle East & Africa varies with country.

Actavis, Inc., Pfizer, Inc., Allergan, Theravence Biopharma US, The Medicines Company, and Merck Millipore are the major players in the global MRSA drugs market. Other promising companies include Cellceutix Corp., Debiopharm International, Kyorin Pharmaceutical, Nabriva Therapeutics, Paratek Pharmaceuticals, and Cempra Pharmaceuticals.

Pre-Book Full Report -

https://www.transparencymarketresearch.com/checkout.php?rep_id=1315<ype=S

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.